Kidney Cancer | Tumor

Opdivo-Yervoy Combo Induces Superior Long-Term Outcomes in Patients with RCC

February 18th 2020

More than 50% of patients with previously untreated advanced or metastatic renal cell carcinoma were alive at 42 months after being treated with Opdivo plus Yervoy.

Childhood Body Mass Index Plays a Role in Kidney Cancer Risk as an Adult

February 13th 2020

Children with higher birth weight and body mass index, as well as taller height, are at a greater risk of developing renal cell carcinoma later in life, according to new study findings.

Anti-PD-1 Therapy May Induce Better Survival Outcomes Compared With Anti-PD-L1

January 15th 2020

Findings from a recent study supported further evaluation of comparing anti–PD-1 to anti–PD-L1 therapy to help determine treatment options for patients with cancer.

Individualized Treatment Plans Improve Outcomes in Kidney Cancer

January 14th 2020

Personalized treatments have changed the cancer landscape, and continue to change it for patients with renal cell carcinoma.

Peer Influence Impacts the Adoption of High-Value Cancer Treatments Over Time

January 9th 2020

A physician’s social network is important to determining the adoption of high-value cancer drugs, as researchers have determined peer influence had a strong association with the adoption of Avastin among oncologists across the nation.

Engaging in Recommended Amounts of Exercise Lowers the Risk of Seven Types of Cancer

January 8th 2020

Doing a few hours of exercise per week can help prevent kidney, liver, endometrial, colon and breast cancers, as well as multiple myeloma and non-Hodgkin lymphoma, a large study found.

"You Have Six Months to Live"

December 24th 2019

FDA Approves Generic for Afinitor for Multiple Indications

December 11th 2019

The Food and Drug Administration approved the first generic for Afinitor, which can provide a safe, effective, lower cost alternative to the brand-name drug it references.

Experimental Targeted Therapy Pill Extends Lives of Patients with Metastatic Renal Cell Carcinoma

December 10th 2019

A phase 3 clinical trial investigating Fotivda improved chances of preventing disease progression in patients with kidney cancer compared with Nexavar.

CURE's Clinical Trial Corner: Kidney Cancer Edition

December 7th 2019

Here is a list of clinical trials that are currently happening within the kidney cancer space.

The Importance of Treatment-Free Survival in Cancer Care Planning

December 5th 2019

In cancer clinical trials, the goal, or primary endpoint, is often focused on overall survival. However, one expert from the Dana Farber Cancer Institute thinks treatment-free survival should also be documented to provide patients with the data they need to make informed treatment choices.

The Search for Biomarkers in Renal Cell Carcinoma

November 9th 2019

When asked about the future of renal cell carcinoma (RCC) treatment, one expert is hopeful about the current search, but notes that more work is needed to find a reliable biomarker for use in patients with the most common kind of kidney cancer.

An Expert Discusses PARP Inhibition, Vaccines and Emerging Therapies in Kidney Cancer

November 3rd 2019

The field of kidney cancer treatment could soon be expanding thanks to the inclusion of PARP inhibitors, vaccination-based strategies and emerging therapies such as Fotivda (tivozanib), according to research presented at the 2019 Kidney Cancer Research Summit.

Kidney Cancer: What Is New in the Second-Line Treatment Setting?

October 21st 2019

Dr. Camillo Porta discussed what is new in kidney cancer beyond the first line of treatment at A Vision of Hope: A Kidney Cancer Educational Symposium.

A One-Two Punch in Kidney Cancer

October 17th 2019

Drug duos that hit kidney cancer with immunotherapy and targeted treatment offer a better alternative to single agents.

Past, Present and Future: How Non-Clear Cell Kidney Cancer Has Evolved

October 17th 2019

Those with non-clear cell kidney cancer have much to look forward to as oncologists’ understanding of the disease is evolving.

Expert Explains Role of Perioperative Therapy in Kidney Cancer

October 16th 2019

Pre- and post-surgical treatment could benefit patients with kidney cancer who are at high risk for disease recurrence.

Kidney Cancer Clinical Trials: What You Need to Know

October 14th 2019

One patient advocate explained how patients with renal cell carcinoma can query about clinical trials and what they need to know about them to do so.

Addressing Nutrition in Patients with Kidney Cancer

October 12th 2019

Nutrition plays a key role in kidney cancer; however, the need to address it is still unmet.

Kidney Cancer: What You Need to Know

October 12th 2019

One expert explained what patients should know about their kidney cancer diagnosis at A Vision of Hope: A Kidney Cancer Educational Symposium.

Early Study Shows Potential Use of Investigational Drug in Patients With Kidney, Lung Cancer

October 5th 2019

The tumors of patients with non-small cell lung and renal cell cancer shrunk following treatment with pegilodecakin plus immunotherapy.

Cancer Survivorship Encouragement

September 30th 2019

Friday Frontline: Cancer Updates, Research and Education on September 13, 2019

September 13th 2019

From a Hallmark Channel actor revealing a kidney cancer diagnosis to a donor match first-time meeting 20 years later, here’s what is making headlines in the cancer space this week.

Targeted Therapies May Benefit Older Patients With Metastatic Renal Cell Carcinoma

July 12th 2019

Patients with renal cell carcinoma who were treated with a targeted therapy lived three months longer than people who received older treatments.

Future of Renal Cell Carcinoma: Hope Is on the Horizon

July 10th 2019

One expert discusses the “extremely interesting and extremely dynamic” field of renal cell carcinoma, and how recent research and FDA actions could offer hope for patients and their doctors.

Collection of Family Cancer History Is Suboptimal, Highlighting Need for Patient Reporting

June 24th 2019

In assessing the quality of family cancer history entered into electronic health records, researchers found that such reporting was suboptimal – highlighting the need to optimize online collection with a provider-free approach.

The Typical Prognosis of Aggressive Renal Cell Cancer

June 24th 2019

The Impact of Support Networks & Multidisciplinary Care

June 24th 2019

Cabozantinib Dose Modification

June 24th 2019

Undergoing Treatment: Cabozantinib Toxicity Management

June 24th 2019